Keyword Connections

•  Iekuni Ichikawa

Resources

• No matching connections

Communities

• No matching connections

Publications

• APOL1 risk variants, race, and progression of chronic kidney disease.
  Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ, AASK Study Investigators, CRIC Study Investigators
  (2013) N Engl J Med 369: 2183-96
• Toward a unified theory of renal progression.
  Harris RC, Neilson EG
  (2006) Annu Rev Med 57: 365-80
• Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis.
  Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I
  (1988) J Clin Invest 82: 322-30
• "Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy.
  Yoshioka T, Shiraga H, Yoshida Y, Fogo A, Glick AD, Deen WM, Hoyer JR, Ichikawa I
  (1988) J Clin Invest 82: 1614-23
• Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance.
  Tian X, Kim JJ, Monkley SM, Gotoh N, Nandez R, Soda K, Inoue K, Balkin DM, Hassan H, Son SH, Lee Y, Moeckel G, Calderwood DA, Holzman LB, Critchley DR, Zent R, Reiser J, Ishibe S
  (2014) J Clin Invest 124: 1098-113
• Experimental autoimmune anti-glomerular basement membrane glomerulonephritis: a protective role for IFN-gamma.
  Kitching AR, Turner AL, Semple T, Li M, Edgtton KL, Wilson GR, Timoshanko JR, Hudson BG, Holdsworth SR
  (2004) J Am Soc Nephrol 15: 1764-74
• Pyridorin in type 2 diabetic nephropathy.
  Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB, Collaborative Study Group
  (2012) J Am Soc Nephrol 23: 131-6
• Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome.
  Drukker A, Eddy AA
  (1998) J Am Soc Nephrol 9: 243-51
• Angiopoietin-2 and glomerular proteinuria.
  de Caestecker MP
  (2007) J Am Soc Nephrol 18: 2217-8
• Sodium intake, ACE inhibition, and progression to ESRD.
  Luther JM
  (2012) J Am Soc Nephrol 23: 10-2
• Regression of existing glomerulosclerosis by inhibition of aldosterone.
  Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB
  (2005) J Am Soc Nephrol 16: 3306-14
• Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions.
  Eddy AA
  (1994) J Am Soc Nephrol 5: 1273-87
• Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality.
  Yoshioka T, Ichikawa I, Fogo A
  (1991) J Am Soc Nephrol 2: 902-12
• Consequences of acute nitric oxide synthesis inhibition in experimental glomerulonephritis.
  Ferrario R, Takahashi K, Fogo A, Badr KF, Munger KA
  (1994) J Am Soc Nephrol 4: 1847-54
• mVps34 deletion in podocytes causes glomerulosclerosis by disrupting intracellular vesicle trafficking.
  Chen J, Chen MX, Fogo AB, Harris RC, Chen JK
  (2013) J Am Soc Nephrol 24: 198-207
• Proteinuria Increases Plasma Phosphate by Altering Its Tubular Handling.
  de Seigneux S, Courbebaisse M, Rutkowski JM, Wilhelm-Bals A, Metzger M, Khodo SN, Hasler U, Chehade H, Dizin E, Daryadel A, Stengel B, NephroTest Study Group, Girardin E, Prié D, Wagner CA, Scherer PE, Martin PY, Houillier P, Feraille E
  (2015) J Am Soc Nephrol 26: 1608-18
• Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats.
  Ma LJ, Jha S, Ling H, Pozzi A, Ledbetter S, Fogo AB
  (2004) Kidney Int 65: 106-15
• Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type IV collagen.
  Abbate M, Kalluri R, Corna D, Yamaguchi N, McCluskey RT, Hudson BG, Andres G, Zoja C, Remuzzi G
  (1998) Kidney Int 54: 1550-61
• Glucocorticoid activates glomerular antioxidant enzymes and protects glomeruli from oxidant injuries.
  Kawamura T, Yoshioka T, Bills T, Fogo A, Ichikawa I
  (1991) Kidney Int 40: 291-301
• Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria.
  Eddy AA, Giachelli CM
  (1995) Kidney Int 47: 1546-57
• Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms.
  Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A
  (1994) Kidney Int 45: 537-43
• A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats.
  Wang JL, Cheng HF, Shappell S, Harris RC
  (2000) Kidney Int 57: 2334-42
• Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
  Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB
  (2000) Kidney Int 58: 1219-27
• Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective.
  Eddy AA, Kim H, López-Guisa J, Oda T, Soloway PD
  (2000) Kidney Int 58: 618-28
• Hypertensive nephrosclerosis in African Americans versus Caucasians.
  Marcantoni C, Ma LJ, Federspiel C, Fogo AB
  (2002) Kidney Int 62: 172-80
• Model of robust induction of glomerulosclerosis in mice: importance of genetic background.
  Ma LJ, Fogo AB
  (2003) Kidney Int 64: 350-5
• Experimental autoimmune Goodpasture's disease: a pathogenetic role for both effector cells and antibody in injury.
  Dean EG, Wilson GR, Li M, Edgtton KL, O'Sullivan KM, Hudson BG, Holdsworth SR, Kitching AR
  (2005) Kidney Int 67: 566-75
• Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria.
  Motoyoshi Y, Matsusaka T, Saito A, Pastan I, Willnow TE, Mizutani S, Ichikawa I
  (2008) Kidney Int 74: 1262-9
• The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.
  Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H
  (2010) Kidney Int 77: 921-7
• Angiotensin actions in the kidney: renewed insight into the old hormone.
  Ichikawi I, Harris RC
  (1991) Kidney Int 40: 583-96
• Hypertension and proteinuria: long-term sequelae of uninephrectomy in humans.
  Hakim RM, Goldszer RC, Brenner BM
  (1984) Kidney Int 25: 930-6
• Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
  Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A
  (1997) Kidney Int 51: 164-72
• PI3-kinase and TGF-β in glomerular nephropathy: which comes first?
  Pozzi A
  (2012) Kidney Int 82: 507-9
• Acute kidney injury is a risk factor for subsequent proteinuria.
  Parr SK, Matheny ME, Abdel-Kader K, Greevy RA, Bian A, Fly J, Chen G, Speroff T, Hung AM, Ikizler TA, Siew ED
  (2018) Kidney Int 93: 460-469
• Blood pressure control, drug therapy, and kidney disease.
  Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D, Lash J, Lipkowitz M, Miller ER, Ojo A, Sika M, Wilkening B, Toto RD, African American Study of Kidney Disease and Hypertension Study Group Investigators
  (2005) Hypertension 46: 44-50
• Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent.
  Matsusaka T, Asano T, Niimura F, Kinomura M, Shimizu A, Shintani A, Pastan I, Fogo AB, Ichikawa I
  (2010) Hypertension 55: 967-73
• Mammalian target of rapamycin inhibitors in organ transplantation: an unkept promise.
  Langone AJ, Helderman JH
  (2012) Chest 142: 734-737
• Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria.
  Golper TA, Illingworth DR, Morris CD, Bennett WM
  (1989) Am J Kidney Dis 13: 312-20
• Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort.
  Toto RD, Greene T, Hebert LA, Hiremath L, Lea JP, Lewis JB, Pogue V, Sika M, Wang X, AASK Collaborative Research Group
  (2010) Am J Kidney Dis 56: 896-906
• A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
  Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J
  (2007) Am J Kidney Dis 50: 946-51